Researchers have explored a new cancer treatment called ECCT and found that it can affect blood vessel growth in breast cancer tumours. This treatment uses electrical fields to target tumours without harming normal breast tissue. The study showed that ECCT increases certain proteins that help form blood vessels in tumours, which might help fight cancer in a new way.

Key Findings:

1. Impact on Angiogenic Gene Expression in Normal Breast Tissues: ECCT exposure did not significantly alter the expression of Hif1α, Sp1, and Vegfa genes in normal breast tissues. This indicates that ECCT does not induce or suppress angiogenesis-related gene expression in non-cancerous cells, suggesting its safety for normal tissues.
2. Impact on Angiogenic Gene Expression in Tumorigenic agent-Induced Tumors: There was a significant increase in Vegfa expression in the INT (induced non-therapy) group, reflecting the tumor’s angiogenic response to Tumorigenic agent induction. Vegfa expression was notably lower in the IT (induced therapy) group following ECCT treatment, suggesting that ECCT effectively downregulates Vegfa expression in tumor tissues and potentially inhibits tumor angiogenesis. In addition, Hif1α expression significantly increased in the INT group, indicating a hypoxic response and angiogenic drive in the tumor. No significant change in Hif1α expression in the IT group post-ECCT treatment suggests that ECCT might mitigate the hypoxic conditions or the tumor’s response to hypoxia.
3. Vegfr2 Gene Expression and Protein Levels: Vegfr2 gene expression remained unchanged with ECCT exposure, supporting that ECCT does not adversely affect angiogenesis in normal tissues. Vegfr2 expression was significantly higher in the IT group compared to the INT group, suggesting that while ECCT downregulates Vegfa, it upregulates Vegfr2, indicating a shift towards Vegfr2-mediated angiogenesis. Immunohistochemistry confirmed increased Vegfr2 protein levels in the IT group, corresponding with the gene expression data. This suggests enhanced angiogenesis via a different pathway facilitated by Vegfr2.
4. Angiogenesis Assessment: The IT group showed a higher number of blood vessels compared to the INT group, indicating that ECCT impacts tumor vasculature. This might be due to the shift towards Vegfr2-mediated angiogenesis, resulting in enhanced blood vessel formation.
5. Safety and Non-Invasive Nature of ECCT: The lack of significant changes in angiogenic gene expression in normal breast tissues under ECCT exposure suggests its safety and minimal impact on non-cancerous cells.The downregulation of Vegfa and stabilization of Hif1α in tumor tissues indicate that ECCT can counteract the tumor’s angiogenic response without inducing significant hypoxia.
6. Mechanism of Action: The study indicates a shift in angiogenic pathways from Vegfa to Vegfr2 under ECCT. Vegfr2 is involved in stable and mature blood vessel formation, which might support immune cell infiltration and anti-tumor immunity. By downregulating primary angiogenic drivers and promoting Vegfr2 pathways, ECCT alters the tumor’s angiogenic landscape, potentially making it more susceptible to immune-mediated tumor suppression.
7. Therapeutic Implications: ECCT offers a non-invasive alternative to traditional therapies, reducing the need for surgical interventions and associated complications. ECCT can be combined with existing treatments, enhancing overall therapeutic efficacy and reducing side effects by modulating angiogenic pathways.

The study observed that exposing breast tumor samples in rats to electric fields led to increased activity in specific genes, potentially influencing the tumor’s behavior. Additionally, it demonstrated the safety of ECCT for healthy organs, particularly the brain and liver, in female rats.

Key Findings

1. Up-Regulation of HMGB1 and PD-L1 in Breast Tumor Tissue: Significant up-regulation of HMGB1 mRNA in the therapy (IT) group compared to the non-therapy (INT) group. Significant up-regulation of PD-L1 mRNA in the IT group, indicating enhanced expression following ECCT exposure. Amplification and melt peak curves confirmed the specificity of the primers used for both genes.
2. No Significant Changes in Brain and Liver Tissues: No significant changes in the expression of HMGB1 and PD-L1 in healthy brain tissues after ECCT exposure. No significant changes in the expression of HMGB1, PD-L1, and interferon-γ in healthy liver tissues post-ECCT exposure.
3. Tumor Microenvironment Impact: ECCT may affect tumor interstitial fluid (TIF) formation, influencing the tumor microenvironment. This disruption can impair the ability of cancer cells to sustain themselves, contributing to tumor shrinkage.
4. Safety and Efficacy: Histopathological observations showed no damage in non-tumor tissues, underscoring the safety of ECCT. This therapy selectively targets cancer cells without affecting normal cells, a crucial advantage over conventional therapies. The absence of histopathological changes in non-tumor tissues reinforces the safety of ECCT, ensuring effective treatment without significant side effects.
5. Modulation of Cellular Proliferation and Apoptosis: Significant up-regulation of HMGB1 in the IT group suggests that ECCT promotes immunogenic cell death (ICD), enhancing the immune response against tumors. PD-L1 up-regulation in the IT group, along with increased CD8+ T cell activity, indicates an anti-tumor immune response rather than immune suppression.
6. Down-Regulation of Inflammatory Cytokines in Tumor Tissue: Significant down-regulation of CCL2 and IL18 in the IT group indicates that ECCT reduces pro-inflammatory and pro-tumorigenic signals. CCL2 is involved in recruiting monocytes and macrophages to the tumor site, while IL18 promotes cell proliferation and migration. Their reduction suggests a less favorable environment for tumor growth and metastasis.

The study shows ECCT stands as a potential novel approach for treating breast cancer. This therapy employs low-intensity, intermediate-frequency electric fields and has exhibited promising outcomes in both laboratory experiments and trials conducted on mice. Research indicated that ECCT not only slowed the growth of cancer cells but also halted the growth of some cells entirely.

Key Findings

In Vitro Findings:

• Growth Inhibition: ECCT exposure significantly inhibited the proliferation of MCF-7 breast cancer cells by 28-39%, with the highest inhibition observed at 24 hours. This suggests that ECCT disrupts cellular processes critical for cancer cell survival and replication.
• Cellular Effects: Cells exposed to ECCT showed reduced proliferation rates and significant cell destruction during mitosis, indicating that ECCT interferes with the normal cell cycle, specifically during cytokinesis, leading to cancer cell death.

In Vivo Findings:

• Tumor Size Reduction: Mice injected with adenocarcinoma cells exhibited a significant tumor size reduction of over 67% following ECCT exposure. This substantial reduction demonstrates the efficacy of ECCT in shrinking tumors without the need for invasive procedures.
• Histopathology: No abnormal histopathological changes were observed in non-tumor tissues of ECCT-treated mice, highlighting the safety of ECCT. Tumor tissues showed extensive macrophage infiltration and the presence of apoptotic cells, suggesting an immune-mediated response to ECCT.
• Tumor Microenvironment: ECCT may alter TIF formation, affecting the tumor microenvironment. Changes in tumor texture suggest that ECCT disrupts the structural integrity of the tumor, potentially impairing cancer cell interactions and growth dynamics.

Safety and Efficacy:

• Histopathological Observations: The absence of damage in non-tumor tissues highlights the safety of ECCT. This is a crucial advantage over many conventional therapies that often harm healthy tissues.
• Selective Action on Tumor Cells: ECCT selectively targets cancer cells without affecting normal cells, minimizing adverse effects and maximizing therapeutic efficacy.

Cellular Proliferation and Apoptosis:

• Reduction in PCNA Expression: PCNA is a marker of cell proliferation. The significant reduction in PCNA expression in the IT group indicates that ECCT effectively inhibits the proliferative capacity of tumor cells, crucial for slowing tumor growth.
• Induction of Apoptosis: The increase in caspase-3 expression signifies enhanced apoptotic activity. ECCT promotes apoptosis, reducing the number of viable cancer cells and contributing to tumor shrinkage.

Inflammatory Cytokines:

• Down-Regulation of CCL2 and IL18: CCL2 and IL18 are involved in promoting inflammation and supporting tumor growth. Their down-regulation indicates a shift towards a less inflammatory and less supportive tumor microenvironment, less conducive to cancer progression.

The study demonstrates that ECCT is not only safe for the liver and kidneys but also spares normal cells from harm. This stands as a significant advantage, addressing a key challenge in cancer treatment—how to target cancer cells without harming healthy ones. The research shows that, in rats, kidney and liver functions declined over time with chemotherapy alone, whereas those receiving ECCT did not experience the same deterioration.

Key Findings

Kidney Histopathology

• Glomerular Injury: No significant differences in glomerular injury scores were observed among the groups, indicating that neither Tumorigenic agent induction nor electric field exposure caused notable glomerular damage.
• Tubular Injury: The Induction Non-Therapy (INT) group had the highest tubular injury score, significantly different from the Induction Therapy (IT) group. This demonstrates the nephrotoxic effect of Tumorigenic agent. ECCT reduced tubular damage, suggesting a protective or reparative effect.
• Interstitial Injury: Inflammation, hemorrhage, and necrosis were observed, but there were no significant differences in interstitial injury scores among the groups.
• Congestion: Tumorigenic agent induction increased congestion, but ECCT exposure potentially reduced congestion, as indicated by the significantly lower congestion scores in the Non-Induction Therapy (NIT) group compared to other groups.

Liver Histopathology

• Cellular Injury: No significant differences in cellular injury scores among the groups. All groups showed close mean values, indicating minimal liver damage from either Tumorigenic agent or ECCT.
• Hemorrhage and Congestion: Tumorigenic agent induction significantly induced hemorrhage, but the congestion score was highest in the IT group, suggesting a synergic effect of Tumorigenic agent and ECCT on vascular congestion.

Blood Plasma Analysis

• Creatinine Levels: Significant increases in creatinine levels in all groups except the IT group post-treatment. The IT group showed a significant decrease, suggesting ECCT may mitigate Tumorigenic agent-induced nephrotoxicity.
• AST and ALT Levels: Both AST and ALT levels increased post-treatment but remained within or close to normal ranges. The IT group exhibited a normalization trend, indicating potential protective effects of ECCT on liver function.

Tumor Microenvironment

• Impact on Tumor Interstitial Fluid (TIF): ECCT may alter TIF formation, affecting the tumor microenvironment. This disruption can impair the ability of cancer cells to sustain themselves, contributing to tumor shrinkage.
• Disruption of Tumor Cell Interactions: The change in tumor texture to a softer, more fluid-like state suggests that ECCT disrupts the structural integrity of the tumor. This could impair the ability of cancer cells to interact with each other and with stromal cells, hindering their growth and proliferation.

Safety and Efficacy

• No Significant Histopathological Injuries: The study found no significant histopathological injuries in the kidney and liver tissues of rats exposed to ECCT, indicating that the therapy is safe for these vital organs.
• Reduction in Tubular Injury: ECCT reduced tubular injury scores in the kidney, suggesting a potential protective effect against Tumorigenic agent-induced nephrotoxicity.
• Normalization of Creatinine Levels: The decrease in creatinine levels in the IT group suggests that ECCT may help maintain or restore normal kidney function.
• Moderate Changes in AST and ALT Levels: While there were changes in AST and ALT levels, they remained within normal ranges, indicating that ECCT does not adversely affect liver function.

Potential Mechanisms

• Reduced Oxidative Stress: The protective effects observed could be due to reduced oxidative stress, as ECCT may improve circulation and reduce ROS levels, which are known to cause cellular damage.
• Enhanced Repair Mechanisms: ECCT may promote tissue repair mechanisms, improving histopathological outcomes and maintaining organ function.

ECCT, by potentially reducing the activity of specific genes within breast tumor cells, holds promise in slowing down their growth. This implication positions ECCT as a potentially groundbreaking approach in the treatment of breast cancer, offering a new avenue for combating this disease.

Key Findings

1. Effective Tumor Inhibition: The IT group showed significantly lower tumor growth rates compared to the INT group, indicating that ECCT effectively inhibits mammary tumor growth. Tumors in the IT group appeared softer and more fluid-like, suggesting altered tumor texture.
2. Histopathological Changes: Tumors in the IT group exhibited necrosis and apoptosis, characterized by blackening and detachment, which indicates effective tumor cell death and sloughing off of dead tissue. The IT group demonstrated significantly lower PCNA expression (p<0.01), indicating reduced cell proliferation, and lower ErbB2 expression (p<0.05), suggesting decreased tumor aggressiveness. Higher expression of caspase-3 (p<0.01) in the IT group indicated increased apoptosis. Additionally, elevated CD68 expression (p<0.01) suggested enhanced macrophage infiltration, likely contributing to tumor regression.
3. Immune Response Modulation: The IT group showed increased infiltration of macrophages likely of the M1 phenotype, promoting an anti-tumor response. Increased CD8+ T cell infiltration in the IT group, leading to a lower CD4/CD8 ratio, which is associated with a stronger anti-tumor immune response.
4. Molecular Analysis: The IT group exhibited significantly lower mRNA expression of CCL2 (15.29 fold change vs. 97.72 in INT) and IL18 (1.34 fold change vs. 2.08 in INT), indicating reduced pro-inflammatory and pro-tumorigenic signals. No significant differences in TNF-α and IL23α expression between IT and INT groups, suggesting these cytokines are not majorly affected by ECCT.
5. Safety and Efficacy: ECCT did not cause damage to non-tumor tissues, indicating its safety. The therapy selectively targets cancer cells, promoting tumor regression without harming normal tissues.

This approach isn’t just about slowing tumor growth; it also plays a significant role in bolstering the body’s natural immune response against the tumor. By leveraging this method, there’s a dual benefit—restraining the tumor’s expansion while empowering the body’s defense mechanisms to better combat and potentially suppress the cancerous growth.

Key Findings

1. Effective Tumor Inhibition: The Therapy (IT) group exhibited significantly lower tumor growth rates compared to the Non-Therapy (INT) group, indicating that ECCT effectively inhibits mammary tumor growth.
2. Histopathological Changes: Tumors in the IT group showed signs of necrosis and apoptosis, including blackening and detachment, leading to healing. The IT group had lower PCNA expression, indicating reduced cell proliferation, while ErbB2 expression remained unchanged. Higher nuclear and hollow region caspase-3 expression in the IT group indicated advanced apoptosis stages facilitated by ECCT.
3. Immune Response Modulation: The IT group had CD68+ macrophages likely of the M1 phenotype, promoting an anti-tumor response. Increased CD8+ T cell infiltration in the IT group with a lower CD4/CD8 ratio, enhancing cytotoxic immune response against tumors.
4. Safety and Efficacy: The study demonstrated that ECCT is safe, with no adverse effects on normal tissues, and effectively reduces tumor growth and modulates the immune response in rats.
5. Non-Invasive: ECCT offers a non-invasive alternative to traditional cancer therapies, potentially reducing side effects and improving patient quality of life.
6. Potential for Combination Therapy: ECCT could be integrated with existing cancer treatments to enhance overall efficacy and target different aspects of tumor biology.

Scientists conducted trials testing a new non-contact method of treating cancer using weak electric fields. These fields, harmless to normal cells, possess the ability to impede the growth and division of cancer cells by affecting their internal structures. In their study, rats with chemically induced breast cancer were exposed to varying strengths of these electric fields. Subsequently, the researchers examined the rats’ kidneys and livers to assess any potential damage caused by the electric fields. Encouragingly, they found no harm inflicted on these organs and even noted a potential positive impact on kidney function in healthy rats. Based on their findings, the scientists concluded that the electric fields are safe for the kidney and liver in rats with breast cancer, advocating further research into optimizing their application and mechanism of action.

Key Findings

• Safety of EF Exposure: Non-contact electric field (EF) exposure at intermediate frequencies does not cause significant histopathological damage to the kidneys and livers of tumor-induced rats, indicating the safety of ECCT.
• Impact on Kidney Histopathology:
  • Tubular Damage: No significant differences in tubular damage scores among the groups, suggesting EF exposure does not exacerbate Tumorigenic agent-induced nephrotoxicity.
  • Interstitial Damage: Significant reduction in renal inflammation and hemorrhage in the NIT group, indicating potential protective effects of EF exposure against oxidative stress and inflammation.
  • Glomerular Damage: No significant differences in glomerular damage, indicating that EF exposure does not impact the structural integrity of glomeruli.
  • Congestion: No significant differences in congestion, implying that EF exposure does not adversely affect renal blood flow.
• Impact on Liver Histopathology:
  • Cellular Damage: No significant cellular damage, indicating that EF exposure is not hepatotoxic and maintains liver cell integrity.
  • Hemorrhage: Higher hemorrhage scores in the NIT group suggest sensitivity of actively dividing liver cells to EF, but no significant damage in tumor-induced rats, indicating a selective effect of EF.
  • Congestion: No significant differences in congestion and no fibrosis observed, indicating no chronic liver damage from EF exposure.
• Renal Protection: The reduction in renal inflammation and hemorrhage scores suggests that EF exposure may mitigate nephrotoxicity, potentially protecting renal function.
• Liver Sensitivity: Higher hemorrhage scores in the NIT group indicate sensitivity to EF in actively dividing liver cells, but the lack of significant damage in tumor-induced rats suggests that EF selectively affects dividing cells without causing extensive harm.
• Non-Invasive and Safe Therapy: ECCT presents a non-invasive treatment option with minimal adverse effects on healthy tissues, addressing the critical need for safer cancer treatments.
• Potential for Combination Therapy: ECCT could be integrated with existing cancer treatments to enhance efficacy while minimizing side effects.
• Therapeutic Implications: The study underscores the potential of ECCT as a non-invasive, safe, and effective cancer treatment modality. The absence of significant adverse effects on the kidneys and liver, coupled with potential protective benefits, highlights the therapeutic value of ECCT.

Researchers have investigated a groundbreaking cancer treatment approach employing electric fields with varying direction and strength. These low-intensity electric fields, harmless to normal cells, disrupt the growth and division of cancer cells by influencing their internal structures. In a study involving rats with chemically induced breast cancer, the subjects were exposed to different electric field strengths. Assessments of two molecules linked to inflammation and immune response in the kidney and spleen indicated no adverse effects on these organs. Notably, there were signs that the electric fields might mitigate inflammation and enhance immune response in rats with breast cancer. The researchers concluded that electric fields are safe for the kidney and spleen in rats with breast cancer, underscoring the necessity for further studies to optimize their application and understand their mechanisms.

Key Findings

1. Impact on IL-10 mRNA Expression in Kidney Tissues: No significant changes in IL-10 mRNA expression were observed in the Non-Induced Non-Therapy (NINT) and Non-Induced Therapy (NIT) groups compared to the control group, indicating that ECCT does not induce substantial anti-inflammatory responses in non-tumor-bearing kidneys. A significant increase in IL-10 mRNA expression was seen in the Induced Non-Therapy (INT) group (p < 0.05), suggesting an inflammatory response to Tumorigenic agent-induced tumors. No significant changes were observed in the Induced Therapy (IT) group, although there were increasing tendencies, indicating that ECCT might have a mild anti-inflammatory effect in the presence of tumors.
2. Impact on IL-10 mRNA Expression in Spleen Tissues: No significant changes in IL-10 mRNA expression were observed across all groups, suggesting that ECCT does not significantly impact the spleen’s inflammatory response, even in tumor-bearing conditions.
3. Impact on TNF-α mRNA Expression in Kidney Tissues: No significant changes in TNF-α mRNA expression were observed across all groups, though there were decreasing tendencies. This indicates that ECCT does not induce a pro-inflammatory response in the kidneys and might slightly suppress pro-inflammatory signals.
4. Impact on TNF-α mRNA Expression in Spleen Tissues: No significant changes in TNF-α mRNA expression were observed across all groups, suggesting that ECCT does not enhance pro-inflammatory responses in the spleen.
5. No Adverse Effects on Normal Inflammatory Response: ECCT exposure did not significantly affect IL-10 and TNF-α mRNA expression in the kidneys of normal rats, indicating that ECCT does not induce harmful inflammatory responses in non-cancerous conditions and is safe for normal tissues.
6. Enhanced IL-10 Expression in Tumor-Bearing Rats: Significant upregulation of IL-10 mRNA in the INT group indicates an inflammatory response to Tumorigenic agent-induced tumors, possibly counteracting inflammation and oxidative stress.
7. TNF-α Expression Dynamics: The absence of significant changes in TNF-α expression across all groups suggests that ECCT does not exacerbate pro-inflammatory responses. The decreasing tendencies in TNF-α expression might indicate an inhibitory effect of IL-10, maintaining a balanced inflammatory response.
8. Non-Invasive and Safe Therapy: ECCT is a non-invasive treatment option with minimal adverse effects on healthy tissues, potentially enhancing the quality of life for cancer patients by reducing treatment-related side effects.
9. Potential for Combination Therapy: ECCT could be combined with other treatments to enhance therapeutic efficacy, leveraging its anti-inflammatory properties to mitigate the side effects of conventional therapies.
10. Safety and Efficacy of ECCT: The study indicates that ECCT does not significantly affect IL-10 and TNF-α expression in kidneys and spleens of rats, whether they have mammary tumors or not, suggesting that ECCT is a safe treatment modality without significant inflammatory or anti-inflammatory responses in vital organs.

Imagine a cancer treatment that’s not only effective but also gentle on the body. That’s what researchers found when they tested a new method called non-contact electric field therapy on rats with breast tumors. This therapy uses low-intensity electric fields to slow down tumor growth, making the tumor cells less harmful. It also boosts the body’s natural defenses and helps kill off cancer cells more efficiently. The best part? It doesn’t cause the harsh side effects often seen with traditional cancer treatments. This could be a game-changer for cancer patients, offering a safer and more tolerable way to fight the disease.

Key Findings

1. Suppression of Tumor Growth:
   • Non-contact electric field therapy significantly suppressed the growth of breast tumors in rats.
   • The therapy group showed a slower rate of tumor nodule growth compared to the untreated group.
2. Improvement in Histological Structure:
   • The therapy group exhibited an improved histological structure of the breast tumor tissue.
   • The connective tissue structure was more clearly defined, with wider lumens and more uniform epithelial cell shape and size.
3. Enhanced Immune Response:
   • Higher expression of CD4 and CD8 proteins was observed in the therapy group.
   • CD4+ lymphocytes, which are crucial for priming CD8+ lymphocytes, were more abundant in the therapy group, indicating a stronger immune response.
4. Increased Apoptosis:
   • The therapy group showed higher expression of caspase-8 and caspase-9 proteins, which are key initiators of apoptosis.
   • The presence of these proteins suggests that the therapy induces a higher rate of apoptosis in tumor cells.
5. Necrosis and Necroptosis:
   • The therapy group had a slightly higher necrosis area, but the difference was not significant.
   • The presence of necroptosis, a form of programmed necrosis, was indicated by the higher expression of caspase-8 and caspase-9.

Clinical Indications

1. Alternative Cancer Therapy:
   • The study provides evidence that non-contact electric field therapy can be an effective alternative to traditional cancer therapies, which often have severe side effects.
   • This therapy can potentially reduce tumor growth and improve the histological structure of tumor tissue.
2. Immune System Activation:
   • The therapy enhances the immune response by increasing the infiltration of CD4+ and CD8+ lymphocytes into the tumor tissue.
   • This immune activation can lead to better tumor cell elimination and control of tumor growth.
3. Induction of Apoptosis:
   • The therapy induces higher levels of caspase-8 and caspase-9, which are crucial for initiating apoptosis.
   • By promoting apoptosis, the therapy can effectively kill cancer cells and prevent tumor progression.
4. Safety and Tolerance:
   • The therapy was shown to be safe, with no significant damage to the kidney and liver.
   • The lack of significant side effects makes this therapy a promising option for cancer patients.
5. Potential for Personalized Medicine:
   • The study suggests that non-contact electric field therapy could be tailored to individual patients based on their specific tumor characteristics and immune response.
   • Further research could explore the optimal frequency and intensity of electric fields for different types of cancer.

Key Findings:

1. Selective Apoptosis:
   • The study demonstrated that Positive Electrostatic Charges (PECs) could selectively induce apoptosis in breast cancer cell lines, including MCF-7 (hormone receptor-positive breast cancer) and MDA-MB-468 (triple-negative breast cancer) cells. The therapy showed significant reductions in cell viability, while normal breast epithelial cells (MCF-10A) were not adversely affected, highlighting the selectivity of PECs.
2. Mechanism of Action:
   • PECs were found to disrupt the cytoskeleton and critical metabolic pathways in cancer cells, leading to apoptosis. This effect was particularly noted in MCF-7 cells, where PECs caused disruptions in the cell cycle and induced apoptosis through the mitochondrial pathway, evidenced by changes in the expression of apoptosis-related proteins. 
   • ​MCF-10A Control: The lack of similar disruptions in MCF-10A cells underscores the specificity of PECs for malignant cells, making it a promising therapeutic approach with minimal risk to normal tissues.
3. In Vivo Validation:
   • The study extended these findings to animal models, where tumors derived from MCF-7 cells were treated with PECs. Significant tumor reduction was observed in the treated animals, with no adverse effects on surrounding normal tissues, indicating that PECs could effectively target tumors without collateral damage.

Clinical Impact:

1. Non-Invasive Cancer Treatment:
   • PEC therapy offers a promising non-invasive treatment option for breast cancer, particularly for patients with tumors that are resistant to standard therapies. The ability to selectively target cancer cells like MCF-7 while sparing normal cells such as MCF-10A could lead to fewer side effects and better overall patient outcomes.
2. Potential for Metastatic and Hormone-Responsive Breast Cancer:
   • Given the effectiveness of PECs in targeting both MCF-7 (hormone receptor-positive) and MDA-MB-468 (triple-negative) breast cancer cells, this therapy could be applied to a broad spectrum of breast cancer subtypes, including those that are metastatic or hormone-responsive.
3. Foundation for Human Trials:
   • The strong preclinical evidence, particularly the selectivity demonstrated in both cancerous (MCF-7, MDA-MB-468) and non-cancerous (MCF-10A) cells, supports the initiation of human trials. Successful human trials could lead to PEC being integrated into treatment protocols for various types of breast cancer.